Literature DB >> 12100227

Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients.

L Bäckman1, H Kreis, J M Morales, H Wilczek, R Taylor, J T Burke.   

Abstract

AIMS: To determine whether bolus doses of methylprednisolone affect the steady-state trough concentrations of sirolimus.
METHODS: Fourteen renal transplant recipients received concentration-controlled sirolimus therapy in combination with azathioprine and steroids (n=8) or mycophenolate mofetil and steroids (n=6). Bolus doses of methylprednisolone (mean total dose over 1-5 days, 1694 mg; range, 500-3000 mg) were given for the treatment of acute rejection. For each patient, the sirolimus dose (mean, 24.1 mg; range, 3.3-52.5 mg) was the same before and during methylprednisolone therapy.
RESULTS: Mean sirolimus whole blood trough concentrations before and after treatment with methylprednisolone were 28.8 ng ml-1 (range, 13.9-45.3 ng ml-1), and 28.5 ng ml-1 (range, 13.0-47.9 ng ml-1), respectively (P=0.85; 95% confidence interval on the difference -3.3, 4.0 ng ml-1).
CONCLUSIONS: Bolus methylprednisolone treatment does not affect steady-state sirolimus trough concentrations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100227      PMCID: PMC1874384          DOI: 10.1046/j.1365-2125.2002.01594.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

Authors:  C G Groth; L Bäckman; J M Morales; R Calne; H Kreis; P Lang; J L Touraine; K Claesson; J M Campistol; D Durand; L Wramner; C Brattström; B Charpentier
Journal:  Transplantation       Date:  1999-04-15       Impact factor: 4.939

2.  Interaction of intravenous methylprednisolone with oral cyclosporin.

Authors:  C S Ubhi; L Woodhouse; G R Giles
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

3.  Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection.

Authors:  D W Holt; T Lee; A Johnston
Journal:  Clin Ther       Date:  2000       Impact factor: 3.393

Review 4.  Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.

Authors:  A MacDonald; J Scarola; J T Burke; J J Zimmerman
Journal:  Clin Ther       Date:  2000       Impact factor: 3.393

5.  High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients.

Authors:  G Klintmalm; J Säwe
Journal:  Lancet       Date:  1984-03-31       Impact factor: 79.321

6.  Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.

Authors:  B D Kahan; B A Julian; M D Pescovitz; Y Vanrenterghem; J Neylan
Journal:  Transplantation       Date:  1999-11-27       Impact factor: 4.939

7.  Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.

Authors:  R W Johnson; H Kreis; R Oberbauer; C Brattström; K Claesson; J Eris
Journal:  Transplantation       Date:  2001-09-15       Impact factor: 4.939

8.  A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.

Authors:  A S MacDonald
Journal:  Transplantation       Date:  2001-01-27       Impact factor: 4.939

9.  Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.

Authors:  B D Kahan
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

10.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.

Authors:  L Pichard; I Fabre; G Fabre; J Domergue; B Saint Aubert; G Mourad; P Maurel
Journal:  Drug Metab Dispos       Date:  1990 Sep-Oct       Impact factor: 3.922

View more
  6 in total

1.  Wide electrochemical window of screen-printed electrode for determination of rapamycin using ionic liquid/graphene composites.

Authors:  Sudkate Chaiyo; Sakda Jampasa; Natnicha Thongchue; Eda Mehmeti; Weena Siangproh; Orawon Chailapakul; Kurt Kalcher
Journal:  Mikrochim Acta       Date:  2020-03-24       Impact factor: 5.833

2.  Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.

Authors:  Wai-Hang Leung; Joel Gay; Unja Martin; Tracy E Garrett; Holly M Horton; Michael T Certo; Bruce R Blazar; Richard A Morgan; Philip D Gregory; Jordan Jarjour; Alexander Astrakhan
Journal:  JCI Insight       Date:  2019-04-30

Review 3.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.

Authors:  Y-P Jin; N M Valenzuela; M E Ziegler; E Rozengurt; E F Reed
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

Review 5.  Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.

Authors:  Dirk R J Kuypers
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology.

Authors:  Amelia-Naomi Sabo; Sarah Jannier; Guillaume Becker; Jean-Marc Lessinger; Natacha Entz-Werlé; Véronique Kemmel
Journal:  Pharmaceutics       Date:  2021-03-30       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.